Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Krystal Biotech, Inc. (KRYS : NSDQ)

• Company Description    Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. Number of Employees: 119

• Price / Volume Information    Yesterday's Closing Price: $59.04 Daily Weekly Monthly 20 Day Moving Average: 187,439 shares Shares Outstanding: 25.64 (millions) Market Capitalization: $1,513.50 (millions) Beta: 0.99 52 Week High: $102.99 52 Week Low: $38.86 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.82% -6.73% 12 Week -5.54% 6.17% Year To Date -15.60% 3.11%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2100 WHARTON STREET SUITE 701 - PITTSBURGH,PA 15203 USA ph: 412-586-5830 fax: - wijem@krystalbio.com http://www.krystalbio.com

• General Corporate Information    Officers Krish S. Krishnan - Chief Executive Officer and President Suma M. Krishnan - Chief Operating Officer Kathryn A. Romano - Chief Accounting Officer Daniel S. Janney - Director Dino A. Rossi - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 501147102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 25.64 Most Recent Split Date: (:1) Beta: 0.99 Market Capitalization: $1,513.50 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.99 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 1.08% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.76 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -33.78% vs. Previous Quarter: -5.32% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -15.99 12/31/21 - -15.03 09/30/21 - -15.01 ROA 03/31/22 - -14.73 12/31/21 - -14.17 09/30/21 - -14.11 Current Ratio 03/31/22 - 7.25 12/31/21 - 17.18 09/30/21 - 9.67 Quick Ratio 03/31/22 - 7.25 12/31/21 - 17.18 09/30/21 - 9.67 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 21.40 12/31/21 - 26.69 09/30/21 - 18.36 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©